Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection

Pituitary

Volumn 12, Issue 3, 2009, Pages 158-164

  Sughrue, Michael E ^a   Chang, Edward F ^a   Tyrell, J Blake ^a   Kunwar, Sandeep ^a   Wilson, Charles B ^a   Blevins Jr , Lewis S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bromocriptine; Outcome; Prolactin; Prolactinoma; Transphenoidal

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADULT; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DIABETES INSIPIDUS; ENDOCRINE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL DISORDER;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROLACTIN; PROLACTINOMA; TREATMENT OUTCOME;

EID: 67849092545     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0135-1     Document Type: Article

References (15)

1. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485-534. doi: 10.1210/ er.2005-9998
2. Wilson CB (1997) Surgical management of pituitary tumors. J Clin Endocrinol Metab 82:2381-2385. doi: 10.1210/jc.82.8.2381
3. Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M (1996) The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol (Oxf) 44:711-716. doi: 10.1046/j.1365-2265.1996.738559.x
4. Bevan JS, Adams CB, Burke CW, Morton KE, Molyneux AJ, Moore RA et al (1987) Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol (Oxf) 26:541-556. doi: 10.1111/j.1365-2265.1987.tb00809.x
5. Landolt AM, Keller PJ, Froesch ER, Mueller J (1982) Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2:657-658. doi: 10.1016/S0140-6736(82)92756-8
6. Faglia G, Moriondo P, Travaglini P, Giovanelli MA (1983) Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet 1:133-134. doi: 10.1016/S0140-6736(83)91782-8
7. Fahlbusch R, Buchfelder M, Rjosk HK, von Werder K (1984) Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma. Lancet 2:520. doi: 10.1016/S0140-6736(84)92596-0
8. Giovanelli M, Losa M, Mortini P, Acerno S, Giugni E (1996) Surgical results in microadenomas. Acta Neurochir Suppl (Wien) 65:11-12
9. Weiss MH, Wycoff RR, Yadley R, Gott P, Feldon S (1983) Bromocriptine treatment of prolactin-secreting tumors: Surgical implications. Neurosurgery 12:640-642
10. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1999) Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results. Neurosurgery 44:254-261. discussion 261-253 doi: 10.1097/00006123-199902000-00006
11. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033. doi: 10.1056/ NEJMoa022657
12. Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58:1179-1183
13. Esiri MM, Bevan JS, Burke CW, Adams CB (1986) Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 63:383-388
14. Takahashi T, Kuwayama A, Katoh T, Kageyama N (1986) Histological changes and operative findings of pituitary adenomas after bromocriptine treatment. Nippon Naibunpi Gakkai Zasshi 62:1336-1351
15. Hankinson SE (2005) Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24:3-15